Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 829 across all filing types
Latest filing 2024-03-28 Audit Report / Informat…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Zevra Therapeutics, Inc. It reports on the non-reliance of previously issued financial statements due to accounting errors and the intention to restate financials in the upcoming 10-K filing. It includes detailed discussion of audit committee conclusions, restatement impacts, and internal control weaknesses. The document also references a press release with financial results and a conference call announcement. The content is focused on audit and financial statement restatement information rather than the full annual report itself. It is not a full Annual Report (10-K), nor is it a simple announcement of a report publication. The detailed audit-related disclosures and the focus on restatement and audit committee conclusions align with the definition of an Audit Report / Information filing (AR). Therefore, the classification is AR with high confidence.
2024-03-28 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 26, 2024, by Zevra Therapeutics, Inc. It announces top-line data from a Phase 2 Clinical Trial and includes a press release as an exhibit. The content focuses on disclosure of clinical trial results and other events, not a full financial report or detailed earnings data. The document is about a specific event disclosure rather than a comprehensive financial or management report. It is not an earnings release, annual report, or interim report. It is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS). The document length (7970 characters) and content confirm it is a full 8-K filing, not just a brief announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2024-03-27 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-3 filed by Zevra Therapeutics, Inc. It discusses the withdrawal of a request for acceleration of the effective date of the Registration Statement. The content is correspondence related to a regulatory filing and does not contain financial statements, audit information, or detailed report data. The document length is short (1826 characters), and it is a formal communication about a regulatory process rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2024-03-06 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Zevra Therapeutics, Inc. It specifically mentions in Item 7.01 Regulation FD Disclosure that the company released an investor presentation on March 5, 2024, which is attached as Exhibit 99.1. The text states that the presentation is intended for use in meetings with investors and is being furnished, not filed, indicating it is a presentation document rather than a full financial report. The document length is 3662 characters, which is relatively short and consistent with an announcement or filing of a presentation rather than a full report. There is no substantive financial data or detailed analysis within the text itself, only a reference to the attached investor presentation. Therefore, the document should be classified as an Investor Presentation (IP).
2024-03-05 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a press release about the FDA extending the review period for a New Drug Application and setting a new action date. The document is relatively short (4060 characters) and includes a press release as an exhibit. It does not contain detailed financial statements or comprehensive financial analysis. The document is an announcement of a regulatory event and a press release, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-03-04 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 22, 2024. It reports amendments to the company's bylaws approved by the board of directors, including proxy rules and disclosure updates. There are no financial statements or detailed financial data presented, only a description of governance changes and filing of amended bylaws as an exhibit. This fits the category of Board/Management Information (MANG) because it announces changes related to corporate governance documents and board-related rules, but does not constitute a full governance report or annual report. The document is not a full financial report, earnings release, or proxy solicitation. Therefore, the best classification is MANG with high confidence.
2024-02-28 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.